Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928277 | 0.89 | BRAF (0.47) | BRAFTNNI3KERBB2IRAK4AAK1 | |
| SCHEMBL9898386 | 0.84 | JAK3 (0.58) | JAK3 | |
| Hydrochloric Acid SCHEMBL9898383 | 0.83 | JAK3 (0.57) | JAK3 | |
| SCHEMBL9928275 | 0.82 | EGFR (0.58) | BRAFTNNI3KABL1EGFRABL2 | |
| SCHEMBL9928281 | 0.81 | AAK1 (0.55) | BRAFTNNI3KERBB2JAK3AAK1 | |
| SCHEMBL9904064 | 0.80 | AAK1 (0.65) | BRAFTNNI3KERBB2AAK1EGFR | |
| SCHEMBL13471636 | 0.78 | BRAF (0.41) | BRAFTNNI3KAAK1ABL1EGFR | |
| SCHEMBL9897618 | 0.75 | AAK1 (0.47) | JAK3AAK1EGFR | |
| SCHEMBL9928273 | 0.74 | EGFR (0.52) | BRAFTNNI3KERBB2EGFR | |
| SCHEMBL9928272 | 0.73 | BRAF (0.45) | BRAFTNNI3KJAK3IRAK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | BRAF 131/4885TNNI3K 372/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.